Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene

1. A double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Serum Amyloid A (SAA) gene, wherein said dsRNA comprises a sense strand and an antisense strand comprising a region of complementarity, wherein said region of complementarity is at least 15 base pairs in length and less than 30 base pairs in length, and wherein said antisense strand and said sense strand are each less than 30 nucleotides in length, and wherein said sense strand comprises at least 15 contiguous nucleotides complementary to SEQ ID NO:194.

2. The dsRNA of claim 1 , wherein the sense strand comprises at least 15 contiguous nucleotides of SEQ ID NO:193.

3. The dsRNA of claim 1 , wherein the antisense strand comprises at least 15 contiguous nucleotides of SEQ ID NO:194.

4. The dsRNA of claim 1 , wherein the sense strand comprises 15 or more contiguous nucleotides of SEQ ID NO:37.

5. The dsRNA of claim 1 , wherein the antisense strand comprises 15 or more contiguous nucleotides of SEQ ID NO:38.

6. The dsRNA of claim 1 , wherein the sense strand consists of SEQ ID NO:37, and the antisense strand consists of SEQ ID NO:38.

7. The dsRNA of claim 1 , wherein at least one nucleotide from said sense strand or said antisense strand comprises a modified nucleotide.

8. The dsRNA of claim 7 , wherein said modified nucleotide is chosen from the group of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.

9. The dsRNA of claim 7 , wherein said modified nucleotide is chosen from the group of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.

10. The dsRNA of claim 1 , wherein the region of complementarity is between 19 and 21 nucleotides in length.

11. The dsRNA of claim 1 , wherein the dsRNA is conjugated to a ligand.

12. The dsRNA of claim 1 , wherein the dsRNA is formulated in a lipid formulation.

13. The dsRNA of claim 1 , wherein the dsRNA is formulated in a LNP formulation, a LNP01 formulation, a LIPID A-SNALP formulation, or a SNALP formulation.

14. The dsRNA of claim 1 , wherein the dsRNA comprises an overhang.

15. The dsRNA of claim 1 , wherein the dsRNA comprises a dTdT overhang.

16. The dsRNA of claim 1 , wherein the dsRNA comprises two dTdT overhangs on the 3′ end of the sense strand and the antisense strand.

17. The dsRNA of claim 1 , wherein the sense strand is 21 nucleotides in length.

18. The dsRNA of claim 1 , wherein the antisense strand is 21 nucleotides in length.

19. A cell containing the dsRNA of claim 1 .

20. A pharmaceutical composition for inhibiting expression of an SAA gene comprising the dsRNA of claim 1 .

21. A method of inhibiting SAA expression in a cell, the method comprising:

(a) introducing into the cell the dsRNA of claim 1 ; and

(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of an SAA gene, thereby inhibiting expression of the SAA gene in the cell.

22. A vector comprising a nucleotide sequence that encodes at least one strand of the dsRNA of claim 1 .

23. A cell comprising the vector of claim 22 .